Some planned price increases for at least 10 drugs were cancelled or reduced after SB 17, California's drug pricing transparency law, went into effect this year. The law requires pharmaceutical companies to give drug purchasers at least 60 days' notice of price increases of more than 16 percent in a two-year period. The Office of Statewide Health Planning and Development (OSHPD) maintains a registry of over 150 public and private purchasers for purposes of the 60-day advance notice requirement. The ACCMA and the California Medical Association supported SB 17. To read more, go to http://www.latimes.com/business/la-fi-drug-prices-20180710-story.html .